Subcutaneous infliximab therapy alone is associated with higher immunogenicity than IV infliximab and an immunomodulator combined.

Dr. James Lee is a Clinician Scientist Group Leader at the Francis Crick Institute (London, UK) and an Honorary Consultant ...

Specific protein signatures could predict a future diagnosis of Crohn disease and ulcerative colitis, potentially enabling ...

A Mediterranean plant shows promise in preventing ulcerative colitis damage in rats, offering a possible safer alternative to ...

New research shows how metabolic activity and thus the communication between intestinal tissue and microbiome collapses ...

Microbial genomics specialist Soma Ghosh and her colleagues have found that people with long-term exposure to arsenic show a ...

Welcome to the realm of irritable bowel syndrome (IBS), a prevalent and chronic disorder that affects over 1 billion ...

Certain GI disorders share microbial biomarkers, with researchers predicting this could lead to new diagnostic tools for ...

Insilico plans late-stage trials for rentosertib following positive mid-stage safety and efficacy data for idiopathic ...

Physician's Weekly has compiled a collection of expert insights on inflammatory bowel disease, focusing on cancer rates and ...

Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® ...

PhotoPill Medical, a leader in innovative therapeutic solutions for gastrointestinal diseases, announced today the initiation of the second part and the enrolment of the first patient, of a clinical ...